1-20 of 29
Fabrice André
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies

Francesco Facchinetti, Yohann Loriot, Floriane Brayé, Damien Vasseur, Rastislav Bahleda, Ludovic Bigot, Rémy Barbé, Catline Nobre, David Combarel, Stefan Michiels, Antoine Italiano, Cristina Smolenschi, Lambros Tselikas, Jean-Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Fabrice André, Ken A. Olaussen, Antoine Hollebecque, Luc Friboulet
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21): 4943–4956.
https://doi.org/10.1158/1078-0432.CCR-24-1834
Published: 01 November 2024
View article titled, Understanding and Overcoming Resistance to Selective FGFR Inhibitors across <em>FGFR2</em>-Driven Malignancies
Open the PDF for Understanding and Overcoming Resistance to Selective FGFR Inhibitors across <em>FGFR2</em>-Driven Malignancies in another window
Includes: Supplementary data
Journal Articles

Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities

Max Piffoux, Jérémie Jacquemin, Mélanie Pétéra, Stéphanie Durand, Angélique Abila, Delphine Centeno, Charlotte Joly, Bernard Lyan, Anne-Laure Martin, Sibille Everhard, Sandrine Boyault, Barbara Pistilli, Marion Fournier, Philippe Rouanet, Julie Havas, Baptiste Sauterey, Mario Campone, Carole Tarpin, Marie-Ange Mouret-Reynier, Olivier Rigal, Thierry Petit, Christine Lasset, Aurélie Bertaut, Paul Cottu, Fabrice André, Ines Vaz-Luis, Estelle Pujos-Guillot, Youenn Drouet, Olivier Trédan
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (20): 4654–4666.
https://doi.org/10.1158/1078-0432.CCR-24-0195
Published: 15 October 2024
View article titled, Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities
Open the PDF for Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities in another window
Includes: Supplementary data
Journal Articles

Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7

Aleix Prat, Nadia Solovieff, Fabrice André, Joyce O'Shaughnessy, David A. Cameron, Wolfgang Janni, Gabe S. Sonke, Yoon-Sim Yap, Denise A. Yardley, Ann H. Partridge, Astrid Thuerigen, Juan Pablo Zarate, Agnes Lteif, Fei Su, Lisa A. Carey
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 793–802.
https://doi.org/10.1158/1078-0432.CCR-23-0561
Published: 16 February 2024
View article titled, Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7
Open the PDF for Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7 in another window
Includes: Supplementary data
Journal Articles

Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients

Sara M. Tolaney, Shom Goel, Jorge Nadal, Hannelore Denys, Manuel R. Borrego, Lacey M. Litchfield, Jiangang Liu, Adams K. Appiah, Yanyun Chen, Fabrice André
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 39–49.
https://doi.org/10.1158/1078-0432.CCR-23-1209
Published: 05 January 2024
View article titled, Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients
Open the PDF for Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors

Naoual Menssouri, Loïc Poiraudeau, Carole Helissey, Ludovic Bigot, Jonathan Sabio, Tony Ibrahim, Cédric Pobel, Claudio Nicotra, Maud Ngo-Camus, Ludovic Lacroix, Etienne Rouleau, Lambros Tselikas, Anne Chauchereau, Félix Blanc-Durand, Alice Bernard-Tessier, Anna Patrikidou, Natacha Naoun, Ronan Flippot, Emeline Colomba, Alina Fuerea, Laurence Albiges, Pernelle Lavaud, Paul van de Wiel, Eveline den Biezen, Yvonne Wesseling-Rozendaal, Santiago Ponce, Stefan Michiels, Christophe Massard, Daniel Gautheret, Fabrice Barlesi, Fabrice André, Benjamin Besse, Jean-Yves Scoazec, Luc Friboulet, Karim Fizazi, Yohann Loriot
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4504–4517.
https://doi.org/10.1158/1078-0432.CCR-22-3736
Published: 01 November 2023
View article titled, Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Open the PDF for Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors in another window
Includes: Supplementary data
Journal Articles

Clinical and Genomic Characteristics of Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors

Xi Rao, Yongmei Chen, Julie Beyrer, Emily Nash Smyth, Claudia Morato Guimaraes, Lacey M. Litchfield, Lee Bowman, Garreth W. Lawrence, Amit Aggarwal, Fabrice Andre
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3372–3383.
https://doi.org/10.1158/1078-0432.CCR-22-3843
Published: 01 September 2023
View article titled, Clinical and Genomic Characteristics of Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors
Open the PDF for Clinical and Genomic Characteristics of Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors in another window
Includes: Supplementary data
Journal Articles

Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor–Positive Breast Cancers

Elie Rassy, Ingrid Garberis, Alicia Tran-Dien, Bastien Job, Véronique Chung-Scott, Ibrahim Bouakka, Josiane Bassil, Rachel Ferkh, Magali Lacroix-Triki, Fabrizio Zanconati, Fabiola Giudici, Daniele Generali, Etienne Rouleau, Ludovic Lacroix, Fabrice Andre, Barbara Pistilli
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (9): 1822–1831.
https://doi.org/10.1158/1078-0432.CCR-22-2883
Published: 01 May 2023
View article titled, Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor–Positive Breast Cancers
Open the PDF for Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor–Positive Breast Cancers in another window
Journal Articles

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Massimo Cristofanilli, Hope S. Rugo, Seock-Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O'Leary, Fabrice André, Sibylle Loibl, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Maria Jose Lechuga Frean, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3433–3442.
https://doi.org/10.1158/1078-0432.CCR-22-0305
Published: 15 August 2022
View article titled, Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
Open the PDF for Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study in another window
Includes: Supplementary data
Journal Articles

Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

Michele L. LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, David M. Hyman, Natalie Blauvelt, Philippe L. Bedard, Funda Meric-Bernstam, Rinaa S. Punglia, Deborah Schrag, Eva M. Lepisto, Fabrice Andre, Lillian Smyth, Semih Dogan, Celeste Yu, Chetna Wathoo, Mia Levy, Lisa D. Eli, Feng Xu, Grace Mann, Alshad S. Lalani, Fei Ye, Christine M. Micheel, Monica Arnedos
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2118–2130.
https://doi.org/10.1158/1078-0432.CCR-21-0885
Published: 13 May 2022
View article titled, Natural History and Characteristics of <em>ERBB2</em>-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE
Open the PDF for Natural History and Characteristics of <em>ERBB2</em>-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE in another window
Includes: Supplementary data
Journal Articles

Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score

C. Benedikt Westphalen, Alexander D. Fine, Fabrice André, Shridar Ganesan, Volker Heinemann, Etienne Rouleau, Clare Turnbull, Luis Garcia Palacios, Jorge-Antonio Lopez, Ethan S. Sokol, Joaquin Mateo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1412–1421.
https://doi.org/10.1158/1078-0432.CCR-21-2096
Published: 01 April 2022
View article titled, Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score
Open the PDF for Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score in another window
Includes: Supplementary data
Journal Articles

Progresses Toward Precision Medicine in RET-altered Solid Tumors

Carmen Belli, Santosh Anand, Justin F. Gainor, Frederique Penault-Llorca, Vivek Subbiah, Alexander Drilon, Fabrice Andrè, Giuseppe Curigliano
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6102–6111.
https://doi.org/10.1158/1078-0432.CCR-20-1587
Published: 01 December 2020
View article titled, Progresses Toward Precision Medicine in <em>RET</em>-altered Solid Tumors
Open the PDF for Progresses Toward Precision Medicine in <em>RET</em>-altered Solid Tumors in another window
Journal Articles

Abstract PO-030: Outcome of older cancer patients infected with Covid19 at Gustave Roussy Cancer Center

Mathilde Hauchecorne, Capucine Baldini, Stéphanie Foulon, Arnaud Bayle, Bertrand Gachot, Fanny Pommeret, Helene Vincent, Tina Lamy, Celine Nagera, Christophe Willekens, Franck Griscelli, Florence Netzer, Corinne Balleyguier, Samy Ammari, Fabrice André, Florian Scotte, Benjamin Besse, Jean-Charles Soria, Fabrice Barlési, Laurence Albigès
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18_Supplement): PO-030.
https://doi.org/10.1158/1557-3265.COVID-19-PO-030
Published: 15 September 2020
View article titled, Abstract PO-030: Outcome of older cancer patients infected with Covid19 at Gustave Roussy Cancer Center
Journal Articles

Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

Rina Hui, Alex Pearson, Javier Cortes, Christine Campbell, Camille Poirot, Hatem A. Azim, Jr, Debora Fumagalli, Matteo Lambertini, Fergus Daly, Amal Arahmani, José Perez-Garcia, Philippe Aftimos, Philippe L. Bedard, Laura Xuereb, Elsemieke D. Scheepers, Malou Vicente, Theodora Goulioti, Sibylle Loibl, Sherene Loi, Marie-Jeanne Pierrat, Nicholas C. Turner, Fabrice Andre, Giuseppe Curigliano
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (2): 354–363.
https://doi.org/10.1158/1078-0432.CCR-19-1164
Published: 15 January 2020
View article titled, Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Open the PDF for Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study in another window
Includes: Supplementary data
Journal Articles

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z. Rizvi, Rosa L. Frias, Jean Paul Thiery, Jean-Yves Scoazec, Tony Sourisseau, Karen Howarth, Olivier Deas, Dariia Samofalova, Justine Galissant, Pauline Tesson, Floriane Braye, Charles Naltet, Pernelle Lavaud, Linda Mahjoubi, Aurélie Abou Lovergne, Gilles Vassal, Rastilav Bahleda, Antoine Hollebecque, Claudio Nicotra, Maud Ngo-Camus, Stefan Michiels, Ludovic Lacroix, Catherine Richon, Nathalie Auger, Thierry De Baere, Lambros Tselikas, Eric Solary, Eric Angevin, Alexander M. Eggermont, Fabrice Andre, Christophe Massard, Ken A. Olaussen, Jean-Charles Soria, Benjamin Besse, Luc Friboulet
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (1): 242–255.
https://doi.org/10.1158/1078-0432.CCR-19-1104
Published: 03 January 2020
View article titled, Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
Open the PDF for Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Angel L. Guerrero-Zotano, Thomas P. Stricker, Luigi Formisano, Katherine E. Hutchinson, Daniel G. Stover, Kyung-Min Lee, Luis J. Schwarz, Jennifer M. Giltnane, Monica V. Estrada, Valerie M. Jansen, Alberto Servetto, Joaquín Gavilá, J. Alejandro Perez-Fidalgo, Ana Lluch, Antonio Llombart-Cussac, Mohamed Amine Bayar, Stefan Michiels, Fabrice André, Mónica Arnedos, Vicente Guillem, Amparo Ruiz-Simon, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1431.
https://doi.org/10.1158/1078-0432.CCR-18-4270
Published: 15 February 2019
View article titled, Correction: ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Open the PDF for Correction: ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors in another window
Journal Articles

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Angel L. Guerrero-Zotano, Thomas P. Stricker, Luigi Formisano, Katherine E. Hutchinson, Daniel G. Stover, Kyung-Min Lee, Luis J. Schwarz, Jennifer M. Giltnane, Monica V. Estrada, Valerie M. Jansen, Alberto Servetto, Joaquín Gavilá, J. Alejandro Perez-Fidalgo, Ana Lluch, Antonio Llombart-Cussac, Mohamed Amine Bayar, Stefan Michiels, Fabrice André, Mónica Arnedos, Vicente Guillem, Amparo Ruiz-Simon, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (11): 2517–2529.
https://doi.org/10.1158/1078-0432.CCR-17-2904
Published: 31 May 2018
View article titled, ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Open the PDF for ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors in another window
Includes: Supplementary data
Journal Articles

A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers

Paul K. Paik, Ronglai Shen, Michael F. Berger, David Ferry, Jean-Charles Soria, Alastair Mathewson, Claire Rooney, Neil R. Smith, Marie Cullberg, Elaine Kilgour, Donal Landers, Paul Frewer, Nigel Brooks, Fabrice André
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (18): 5366–5373.
https://doi.org/10.1158/1078-0432.CCR-17-0645
Published: 14 September 2017
View article titled, A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
Open the PDF for A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers in another window
Includes: Supplementary data
Journal Articles

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, Linda Mahjoubi, Ludovic Lacroix, David Planchard, Benjamin Besse, Françoise Farace, Nathalie Auger, Jordi Remon, Jean-Yves Scoazec, Fabrice André, Jean-Charles Soria, Luc Friboulet
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (24): 5983–5991.
https://doi.org/10.1158/1078-0432.CCR-16-0917
Published: 15 December 2016
View article titled, Crizotinib-Resistant <em>ROS1</em> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <em>ROS1</em>- and <em>ALK</em>-Rearranged Lung Cancers
Open the PDF for Crizotinib-Resistant <em>ROS1</em> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <em>ROS1</em>- and <em>ALK</em>-Rearranged Lung Cancers in another window
Includes: Supplementary data
Journal Articles

Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial

Cécile Jovelet, Ecaterina Ileana, Marie-Cécile Le Deley, Nelly Motté, Silvia Rosellini, Alfredo Romero, Celine Lefebvre, Marion Pedrero, Noémie Pata-Merci, Nathalie Droin, Marc Deloger, Christophe Massard, Antoine Hollebecque, Charles Ferté, Amélie Boichard, Sophie Postel-Vinay, Maud Ngo-Camus, Thierry De Baere, Philippe Vielh, Jean-Yves Scoazec, Gilles Vassal, Alexander Eggermont, Fabrice André, Jean-Charles Soria, Ludovic Lacroix
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2960–2968.
https://doi.org/10.1158/1078-0432.CCR-15-2470
Published: 14 June 2016
View article titled, Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial
Open the PDF for Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial in another window
Includes: Supplementary data
Journal Articles

Targeting FGFR Signaling in Cancer

Mehdi Touat, Ecaterina Ileana, Sophie Postel-Vinay, Fabrice André, Jean-Charles Soria
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2684–2694.
https://doi.org/10.1158/1078-0432.CCR-14-2329
Published: 14 June 2015
View article titled, Targeting FGFR Signaling in Cancer
Open the PDF for Targeting FGFR Signaling in Cancer in another window